ERVEBO® [Ebola Zaire Vaccine] Awarded Prequalification Status by the World Health Organization (WHO)

Content provided by APO Group. CNBC Africa provides content from APO Group as a service to its readers, but does not edit the articles it publishes. CNBC Africa is not responsible for the content provided by APO Group.
Download logo

Merck (NYSE: MRK), known as MSD (www.MSD.com) outside the United States and Canada, today announced that ERVEBO [Ebola Zaire Vaccine (rVSVΔ-ZEBOV-GP live)] has been awarded prequalification status by the World Health Organization (WHO).  ERVEBO is the first vaccine to be prequalified by the WHO for the prevention of Ebola Virus Disease.  WHO prequalification follows the European Commission’s grant of a conditional marketing authorization to ERVEBO on November 11, 2019.  ERVEBO is currently under Priority Review with the U.S. Food and Drug Administration (FDA) with a target action date of March 14, 2020.

WHO prequalification means that ERVEBO has met the WHO’s standards of quality, efficacy and tolerability, which, in conjunction with other criteria, offers guidance to the United Nations (UN) and other global health entities in making relevant vaccine decisions.  Importantly, prequalification status allows a vaccine to be procured and purchased by the UN, now allowing ERVEBO to be considered as a vaccine to be included in a global Ebola vaccines stockpile being planned by the WHO, UNICEF, Gavi (the Vaccines Alliance), and others.  

In addition to the submission to the FDA, MSD has also made submissions to selected African country National Regulatory Authorities in collaboration with WHO-AFRO and the African Vaccine Regulatory Forum (AVAREF), which, if approved, will allow the vaccine to be registered in those countries.

MSD’s Commitment to Infectious Diseases For more than 100 years, MSD has contributed to the discovery and development of novel medicines and vaccines to combat infectious diseases. In addition to a combined portfolio of vaccines and antibacterial, antiviral and antifungal medicines, MSD has multiple programs that span discovery through late-stage development. To learn more about MSD’s infectious diseases pipeline, visit www.MSD.com.

About MSD For more than a century, MSD, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world – including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information, visit www.MSD.com and connect with us on Twitter (https://bit.ly/2CGExWv) , Facebook (https://bit.ly/2QlopBY), Instagram (https://bit.ly/350ebuJ), YouTube (https://bit.ly/33O9owv) and LinkedIn (https://bit.ly/2Oein3k).

Forward-Looking Statement of MSD: This news release of MSD (known as Merck & Co., Inc., Kenilworth, N.J. in the USA (the “company”)) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2018 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Distributed by APO Group on behalf of MSD.

Media Contact: Neren Rau +27 11 6553000                

Related Content

AfDB forecasts Africa’s growth in 2021

Updated forecasts from the African Development Bank show that Africa’s growth is expected to rebound to 3 per cent by 2021 from a 3.4 per cent contraction in 2020 in the worst-case-scenario. Hanan Morsy, Director for Macroeconomic Forecasting and Research at the AfDB joins CNBC Africa for more.

City Lodge faces resistance to its R1.2bn rights issue. Here’s why

In the wake of COVID-19 many listed companies have offered rights issues in order to raise capital during these trying times, but according to Oasis Asset Management there are good and bad equity issuances. Joining CNBC Africa for more is Adam Ebrahim, CEO of Oasis Asset Management.

Surgo Foundation: Why a young population is Africa’s best defence against coronavirus

Africa’s young population is the best defence against the COVID-19 pandemic, as the COVID-19 mortality rate for key populations has shown age as a factor for hospitalizations. This is according to the latest study by the Africa COVID-19 Community Vulnerability Index; CNBC Africa spoke to Dr. Sema Sgaier, Executive Director at the Surgo Foundation for more.

Professor Shabir Madhi gives update on SA’s first COVID-19 vaccine trials

It’s been almost three weeks since South Africa’s first COVID-19 vaccine trials began, we will be unpacking more on the progress of these trials as well as the latest emerging evidence brought to the attention of the World Health Organization regarding the airborne transmission of COVID-19. Joining CNBC Africa for more is Shabir Madhi, Professor of Vaccinology at the University of Witwatersrand.

Subscribe to our newsletter

Sign up for free newsletters and get more CNBC AFRICA delivered to your inbox

More from CNBC Africa

Does the Competition Competition have capacity to clamp down on COVID-19 profiteering?

As South Africa sees a surge in COVID-19 infections, consumers are increasingly faced with overpriced products on the shelves. The Competition Commission continues to receive complaints, from customers who are already feeling the pinch. The question is, does the Competition Competition have the capacity to clamp down on price gouging? Joining CNBC Africa for this discussion is Makgale Mohlala, Head of Cartels at the Competition Commission and Shawn van der Meulen, Partner at Webber Wentzel.

Uganda’s central bank may cap commercial bank interest rates

KAMPALA (Reuters) - Uganda’s central Bank (BoU) has threatened to cap the interest that commercial banks can charge borrowers, after the industry...

Jambojet set to resume domestic flights on July 15

Jambojet gears up for local flight resumption; lower oil imports and higher tea exports spell current account improvement and the Central Bank invites bids for millions in treasury bonds. Journalist, Joseph Bonyo joins CNBC Afric for more.

Chamber launches business clinics to support women-led businesses

Rwanda’s women entrepreneurs arm under the private sector federation body has launched a series of business clinics with the aim of supporting women-led businesses affected by the Covid-19 pandemic. CNBC Africa spoke to Agnes Samputu, Executive Director of the Rwanda Chamber of Women Entrepreneurs for more.

Partner Content

Maktech’s Godwin Makyao: Now Is A Time of Entrepreneurial Opportunity in East Africa

As an executive decision-maker in both the telecommunications and tourism industries, Godwin Makyao could not have experienced a more diverse set of...

Sanlam launches urgent job-preservation initiative in response to COVID-19

Sanlam Investments is responding to the COVID-19 pandemic through large-scale support of the recovery of South African companies, from small enterprises to...

Trending Now

Africa urged to test more as coronavirus cases exceed 500,000

The African Union Commission said on Thursday it had launched a consortium for vaccine clinical trials to be headed by the Africa CDC, which aimed to secure more than 10 late stage vaccine clinical trials as early as possible.

Malawi’s new female cabinet ministers vow to push for jobs for women

Women now hold 39% of the ministerial and deputy minister roles in the cabinet appointed by Chakwera, 65, who unseated Peter Mutharika in a re-run presidential election last month, which compared to about 20% in the previous government.

Dow, S&P 500 end lower on fears over surging virus cases but Nasdaq hits record high

he Nasdaq hit another record high, however, helped by gains in Amazon.com (AMZN.O), Microsoft Corp (MSFT.O) and Apple Inc (AAPL.O).

Eskom goes after contractors over R4bn Kusile over-payment

One of the power stations that were meant to be the saviour of South Africa’s power supply is causing controversy, even before it’s in full working order. In an explosive letter, Public Enterprises Minister Pravin Gordhan named contractors that he says Eskom over-paid by R4 billion, in the construction of Kusile power station. Sikonathi Mantshantsha, National Spokesperson of Eskom joins CNBC Africa for more
- Advertisement -